| Name | Title | Contact Details |
|---|
Gardenvision is a Miami, FL-based company in the Business Services sector.
Headquartered in Livermore, California, Livermore Software Technology Corporation (LSTC) develops LS-DYNA and a suite of related and supporting engineering software products. LSTC was founded in 1987 by John O. Hallquist to commercialize as LS-DYNA the public domain code that originated as DYNA3D. DYNA3D was developed at the Lawrence Livermore National Laboratory, by LSTCs founder, John O. Hallquist. A team of engineers, mathematicians, and computer scientists are engaged in the development of LS-DYNA, LS-PrePost, and LS-OPT for use in various industries, including Automobile Design, Aerospace, Manufacturing, and Bioengineering. LS-DYNA development is focused on one code methodology that includes Implicit, Explicit, SMP and MPP solvers. It is optimized on all platforms including clusters running Unix, Linux, and Windows operating systems.
Official Twitter of the Office of the Governor of California Gavin Newsom. #CaliforniaForAll 📍For the latest #COVID19 information ➡️https://t.co/84A7r5WtRo
At enGene, we are at the vanguard of a new era in genetic medicine: Our novel Dually Derivatized Oligochitosan® (DDX) gene delivery platform is designed to enable localized delivery of multiple gene cargos, including RNA and DNA, directly to mucosal tissues and other organs — potentially overcoming the limitations of viral-based gene therapies and advancing gene therapy beyond rare genetic diseases into the mainstream of clinical practice. Our breakthrough Dually Derivatized Oligochitosan® (DDX) platform opens possibilities for streamlining the use of genetic medicines in the treatment of serious diseases, especially diseases afflicting mucosal tissues. Our lead product candidate, EG-70 (detalimogene voraplasmid), is a non-viral immunotherapy in development to treat non-muscle invasive bladder cancer (NMIBC), a disease with a significant patient burden, high clinical needs, and massive healthcare system economic impact. Based on its preliminary efficacy and safety profile and ease of administration by urologists, EG-70, which is currently in a pivotal trial, can potentially benefit patients across a wide variety of clinical settings. As enGeneers, we are boldly focused on patients needs. We are a team of passionate experts with extensive experience in drug development and commercialization across oncology, respiratory, and several other therapeutic areas. Nasdaq: ENGN
Beacon is a company that provides a platform to buy and sell small businesses. They offer business valuations, acquisition financing, and resources for both buyers and sellers.